Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccination Schedule Seven-University of Oxford-malaria
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaccination Schedule Seven-University of Oxford-malaria refers to a specific heterologous prime-boost vaccination regimen developed by the University of Oxford's Jenner Institute for the prevention of malaria. This regimen consists of two viral vector vaccines: ChAd63 ME-TRAP (chimpanzee adenovirus 63) and MVA ME-TRAP (Modified Vaccinia Ankara). Both vectors are engineered to express the ME-TRAP antigen, which is a fusion of a multi-epitope (ME) string and the thrombospondin-related adhesion protein (TRAP) from *Plasmodium falciparum*. The 'Schedule Seven' protocol specifically involves a priming dose of ChAd63 ME-TRAP at day 0, followed by two booster doses of ChAd63 ME-TRAP at weeks 8 and 16, and a final booster dose of MVA ME-TRAP at week 24. This approach aims to induce high levels of antigen-specific T cells to target the liver stage of the malaria parasite.
- Other names
- Vaccination Schedule SevenChAd63 ME-TRAP + MVA ME-TRAPME-TRAP vaccine
02
Targets
TRAP (Thrombospondin-related anonymous protein)ME (Protocadherin beta-11)
Beyond the preview
Go deeper on Vaccination Schedule Seven-University of Oxford-malaria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccination Schedule Seven-University of Oxford-malaria.